Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07632222

High-Protein Diet for Improving Alcoholic Fatty Liver Disease

Alcohol-associated liver disease (ALD) is a major cause of mortality from malignant liver diseases, accounting for 47.9% of cirrhosis-related deaths and 30% of liver cancer-related deaths annually. In China, both alcohol consumption and the prevalence of ALD (approximately 5.15%) are on the rise, making ALD an increasingly significant health concern for the population. Alcohol-associated fatty liver disease (AFLD), as the initial and most reversible stage of ALD, is primarily characterized by excessive hepatic lipid deposition, mild liver injury accompanied by mild inflammation. It can progressively develop into alcoholic hepatitis, and in some patients, advance to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Currently, there is a lack of effective clinical treatments for AFLD. Although alcohol abstinence remains the optimal choice for reversing AFLD, it is often difficult for individuals with alcohol dependence to maintain.

A high-protein diet generally refers to a dietary pattern where protein accounts for more than 20% of total energy intake. A protein contribution of 30% is a common ratio in research investigating high-protein dietary interventions for metabolic diseases. Population-based intervention studies have demonstrated that a high-protein diet at this ratio significantly reduces hepatic fat content. For instance, a study published in Gastroenterology (2017) reported that a 6-week isocaloric high-protein diet (macronutrient distribution: 30% protein, 40% carbohydrates, 30% fat) significantly improved hepatic lipid deposition in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Research in Diabetologia (2019) showed that a 6-week isocaloric high-protein diet (30% protein, 30% carbohydrates, 40% fat) significantly reduced hepatic fat content in patients with T2DM. Additionally, a study in Liver International (2020) indicated that a 3-week energy-restricted high-protein diet (30% protein, 35%-45% carbohydrates, 25%-30% fat) significantly decreased hepatic fat content in NAFLD patients. Importantly, none of the aforementioned studies reported adverse events associated with the high-protein dietary interventions. Furthermore, a population-based intervention study published in Annals of Internal Medicine revealed that a low-carbohydrate, high-fat diet was more effective than a high-carbohydrate, low-fat diet in reducing hepatic fat content over a 6-month period in patients with NAFLD and T2DM. These findings suggest that increasing the percentage of energy from protein by reducing carbohydrate intake may yield superior improvements. Based on the macronutrient distributions from the referenced population interventions, and considering that a 30% fat energy contribution closely aligns with the typical dietary fat intake of the Chinese AFLD population, we established the macronutrient distribution for the high-protein diet group as 30% protein, 40% carbohydrates, and 30% fat.

This study intends to conduct a randomized controlled trial to investigate the effects of increasing the percentage of energy from protein under an isocaloric dietary pattern on liver function, hepatic fat content, and glucose-lipid metabolism in individuals with AFLD. The aim is to elucidate the mechanisms underlying its beneficial effects on AFLD, thereby providing population-based evidence and strategies for health promotion in this patient group.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 30 and 65 years old.
  • Able to understand the study and voluntarily sign the informed consent form.
  • Meet the clinical diagnostic criteria for alcohol-associated fatty liver disease (AFLD): a history of alcohol consumption for ≥5 years, with an average daily ethanol intake of ≥20 g/d; clinically diagnosed with fatty liver (indicated by abdominal ultrasound or a liver MRI proton density fat fraction [MRI-PDFF] ≥5.2%).

Exclusion criteria

  • Average daily ethanol intake >80 g/d.
  • Presence of other hepatobiliary diseases, such as autoimmune liver disease, viral hepatitis, liver fibrosis, or cirrhosis.
  • Presence of severe cardiovascular or cerebrovascular diseases, or renal insufficiency.
  • Patients with tumors or other severe systemic diseases.
  • Patients with gastrointestinal disorders, or those with known protein allergy or intolerance.
  • Long-term use of medications known to cause hepatic steatosis or steatohepatitis (e.g., amiodarone or tamoxifen), nutritional supplements, or probiotics.
  • Total daily energy intake (excluding energy from alcohol) <1900 kcal or ≥2900 kcal.
  • Participation in another interventional study within the past year, or scheduled to receive non-study treatments during the trial period.

Treatment and study plan

high protein diet

Dietary Supplement

high protein diet

control diet

Dietary Supplement

control diet

perilla peptide dietary group

Dietary Supplement

perilla peptide dietary group

Primary outcomes

  1. Magnetic Resonance Imaging proton density fat fraction in hepatic steatosis

    Time frame: Baseline, up to 60 days of the study

    Magnetic Resonance Imaging (MRI) technology utilizes magnetic fields and radiofrequency pulses to conduct non-invasive examinations of tissues. When measuring liver fat content, MRI employs water-fat separation techniques to quantify the proton density of water molecules and fat molecules (PDFF) within the liver, thereby providing a quantitative analysis of fat content.

Secondary outcomes

  1. Liver function

    Time frame: Baseline, up to 60 days of the study

    Alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), γ-glutamyltransferase (γ-GT, U/L), alkaline phosphatase (ALP, U/L), total bilirubin (TBIL, μmol/L), direct bilirubin (DBIL, μmol/L), indirect bilirubin (IBIL, μmol/L), alcohol dehydrogenase (ADH, U/L), aldehyde dehydrogenase (ALDH, U/L).

  2. Glucose metabolism

    Time frame: Baseline, up to 60 days of the study

    Hemoglobin A1c (HbA1c, %), Fasting blood glucose (FBG, mmol/L)

  3. Lipid metabolism

    Time frame: Baseline, up to 60 days of the study

    Serum triglycerides (TG, mmol/L), total cholesterol (TC, mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein cholesterol (HDL-C, mmol/L), apolipoprotein A-I (ApoA-I, g/L), apolipoprotein B (Apo B, g/L).

Other outcomes

  1. Inflammation level

    Time frame: Baseline, up to 60 days of the study

    High-sensitivity C-reactive protein (hs-CRP, mg/L), tumor necrosis factor (TNF-α, pg/mL), interleukins (IL-1β, pg/mL), interleukins (IL-6, pg/mL).

  2. Kidney function

    Time frame: Baseline, up to 60 days of the study

    Blood creatinine (CREA, μmol/L), urea nitrogen (BUN, mmol/L), uric acid (UA, μmol/L).

  3. Intestinal flora

    Time frame: Baseline, up to 60 days of the study

    16s rRNA sequencing

  4. serum untargeted metabolomics

    Time frame: Baseline, up to 60 days of the study

    serum untargeted metabolomics

  5. biomarkers of oxidative stress

    Time frame: Baseline, up to 60 days of the study

    Urinary 8-isoprostane(pg/mL)

Study contacts

Contact information is provided by the study sponsor or research team.

Kaixin Pan

CONTACT

[email protected]

+8613568620076

Qingling Huang, Dr.

CONTACT

[email protected]

+8615267148306

Sponsors and collaborators

Lead sponsor

Li Lab,MD

Other Gov

Collaborators

  • Harbin Medical University

Registry information

Official study title

Efficacy and Safety of a High-Protein Diet Versus a Standard Diet in Patients With Alcoholic Fatty Liver Disease: A Randomized Controlled Trial

Acronym: HP-AFLD-RCT

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jun 8, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.